Kirian Claeyé

The newest Partner at ALTIUS, Kirian specialises in intellectual property and regulatory affairs relating to the pharmaceutical field.

His IP work focuses on complex patent litigation, often involving cross-border issues, parallel trade disputes, and support and advice regarding IP portfolio management. His regulatory work spans the fields of launch and marketing strategies, pricing and reimbursement, tendering, advertising, and lifecycle management.

Kirian is a member of the Boalt Hall Alumni Association, (Young) EPLAW, Licensing Executives Society, and the Belgian American Educational Foundation (BAEF).

• “Evoluties in het octrooirecht – Overzicht van rechtspraak 2018-2022”, TBH 2022, 435-489 (co-author)

• “Vrijwaring voor uitwinning en intellectuele eigendom” in B. Tilleman & B. Devolder, Weens Koopverdrag, Brugge, Die Keure, 2022, pp. 551-618 (co-author)

• “Pharmaceutical IP and Competition law in Belgium: Overview”, Thomson Reuters, 1 August 2021 (co-author)

• “Must AstraZeneca supply the EU with sufficient COVID-19 vaccines?”, ILO Healthcare & Life Sciences, 10 February 2021 / Mondaq, 13 April 2021

• “Belgium” in J. Bühling, Patent Protection for Second Medical Uses, The Netherlands, Kluwer, 2020 (co-author)

• The Pharma Legal Handbook: Belgium, PharmaBoardroom 2020 (co-author)

• “Evoluties in het octrooirecht – Overzicht van rechtspraak 2014-2018”, TBH-RDC 2018, 747-798 (co-author)

Additionally Kirian regularly speaks at conferences and seminars, is host of ALTIUS’ annual Pharma Law Seminar, and in charge of ALTIUS’ two-monthly Life Sciences Sessions.